Investigating Ficerafusp Alfa Plus Pembrolizumab in HPV-Negative Head and Neck Cancer
John Kaczmar, MD, MUSC Hollings Cancer Center, Charleston, South Carolina, discusses the unmet need for more effective first-line treatments for recurrent or metastatic HPV-negative head and neck squamous cell carcinoma and the rationale for combining EGFR/TGF-β targeting with pembrolizumab.
He outlines the FORTIFI-HN01 trial, including its patient population, randomized design, and primary end points of objective response rate and overall survival. Reflecting on encouraging findings from the separate phase 1 study, he explains why improved tumor response, symptom relief, and longer survival are important goals for the ongoing trial.
Transcript:
Hi there. I’m John Kaczmar. I’m a head and neck medical oncologist, and I’m going to talk a little bit today about a trial in progress, the FORTIFI-HN01 study, which is focused on HPV-negative head and neck cancer patients with squamous cell carcinoma who have not had any prior treatment in the recurrent or metastatic setting.
This is an area of huge unmet need. Patients with recurrent and metastatic HPV-negative head and neck squamous cell cancer have relatively few standard-of-care options currently. We treat patients with immunotherapy in the form of pembrolizumab or chemotherapy with pembrolizumab. Those are generally our first-line treatment options. And responses are modest, and progression generally happens on the order of a number of months.
It’s very important that we be investigating some of these important new therapies that will hopefully change the game in HPV-negative cancer, increasing response rates, improving progression-free survival, and most importantly, helping our patients live longer.
The FORTIFI-HN01 study is evaluating the addition of ficerafusp alfa to pembrolizumab. It’s being compared against pembrolizumab monotherapy, and this is for patients with a CPS of 1 or greater.
The idea of adding ficerafusp alfa is based on its mechanism of action. This is a bispecific antibody with an EGFR-targeting component as well as a TGF-beta trap. The idea is that the EGFR component helps target the tumor itself, as EGFR is overexpressed in squamous cell cancers of the head and neck. And the TGF-beta component is there to enable tumor penetration by immune cells by trying to break down the tumor microenvironment that can be immunosuppressive in a lot of these patients.
The idea is that there’s synergy in adding this therapy to pembrolizumab, with the goal of deeper and improved responses and, again, an increase in overall survival.
The FORTIFI-HN01 study is focused on, again, first-line recurrent or metastatic head and neck squamous cell carcinoma patients. The regions are the oral cavity, hypopharynx, larynx, and oropharynx, and those patients need to be HPV-negative. Again, it’s for a CPS of 1 or greater, and it’s a 2-to-1 randomization between ficerafusp alfa and pembrolizumab versus pembrolizumab plus placebo. So it’s a randomized, double-blind, placebo-controlled study.
Initially, the study evaluated two different doses of ficerafusp alfa, 1500 milligrams and 750 milligrams, and the final dose has been decided as 1500 milligrams. And it’s now in the phase 3 portion of the study, comparing that dose and pembrolizumab versus placebo and pembrolizumab.
The primary objectives for the study are comparing objective response rate and overall survival of the combination versus pembrolizumab alone. And secondary outcomes include safety, progression-free survival, and patient-reported outcomes.
This is a very important study. Again, treatment options for HPV-negative head and neck squamous cell carcinoma patients are limited, and efficacy is modest at best. We need better treatment options.
Ficerafusp alfa in the phase 1 study has shown really encouraging activity, very deep responses, with a significant portion of patients having complete responses—over 20% of patients in some of the phase 1 cohorts—suggesting that this is a really active therapy and will hopefully improve on our highest objective response rate of a phase 3 study in the frontline, which is chemotherapy and immunotherapy with about a 35% response rate, which means a significant portion of patients don’t benefit from our current standard of care.
Hopefully, this treatment will offer improved response rates because it’s important. These patients have a lot of symptoms, so if we can shrink their cancer, it’s truly going to help their symptoms. And again, most importantly, improving overall survival, taking it well past the slight bit over a year that it currently is in HPV-negative patients.
Data, again, in the phase 1 study have been very encouraging, so we’re hoping that we will see this phase 3 study read out in a manner that supports an improvement in the combination versus pembrolizumab alone. These patients need it, and we’re hopeful.


